Review Article

Tacrine Derivatives in Neurological Disorders: Focus on Molecular Mechanisms and Neurotherapeutic Potential

Saikat Mitra, Maniza Muni, Nusrat Jahan Shawon, Rajib Das, Talha Bin Emran, Rohit Sharma, Deepak Chandran, Fahadul Islam, Md. Jamal Hossain, Sher Zaman Safi, and Sherouk Hussein Sweilam

1Department of Pharmacy, Faculty of Pharmacy, University of Dhaka, Dhaka 1000, Bangladesh
2Department of Pharmacy, BGC Trust University Bangladesh, Chittagong 4381, Bangladesh
3Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, Dhaka 1207, Bangladesh
4Department of Rasa Shastra and Bhaishajya Kalpana, Faculty of Ayurveda, Institute of Medical Sciences, Banaras Hindu University, Varanasi, 221005 Uttar Pradesh, India
5Department of Veterinary Sciences and Animal Husbandry, Amrita School of Agricultural Sciences, Amrita Vishwa Vidyapeetham University, Coimbatore, Tamil Nadu 641009, India
6Department of Pharmacy, State University of Bangladesh, 77 Satmasjid Road, Dhanmondi, Dhaka 1205, Bangladesh
7Faculty of Medicine, Bioscience and Nursing, MAHS University, Jenjarom, 42610 Selangor, Malaysia
8IRCBM, COMSATS University Islamabad, Lahore Campus, Lahore, Pakistan
9Department of Pharmacognosy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia
10Department of Pharmacognosy, Faculty of Pharmacy, Egyptian Russian University, Cairo-Suez Road, Badr City 11829, Egypt

Correspondence should be addressed to Talha Bin Emran; talhabmb@gmail.com

Received 10 June 2022; Revised 19 July 2022; Accepted 3 August 2022; Published 18 August 2022

Academic Editor: Yujie Chen

Copyright © 2022 Saikat Mitra et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Tacrine is a drug used in the treatment of Alzheimer’s disease as a cognitive enhancer and inhibitor of the enzyme acetylcholinesterase (AChE). However, its clinical application has been restricted due to its poor therapeutic efficacy and high prevalence of detrimental effects. An attempt was made to understand the molecular mechanisms that underlie tacrine and its analogues influence over neurotherapeutic activity by focusing on modulation of neurogenesis, neuroinflammation, endoplasmic reticulum stress, apoptosis, and regulatory role in gene and protein expression, energy metabolism, Ca 2+ homeostasis modulation, and osmotic regulation. Regardless of this, analogues of tacrine are considered as a model inhibitor of cholinesterase in the therapy of Alzheimer’s disease. The variety both in structural make-up and biological functions of these substances is the main appeal for researchers’ interest in them. A new paradigm for treating neurological diseases is presented in this review, which includes treatment strategies for Alzheimer’s disease, as well as other neurological disorders like Parkinson’s disease and the synthesis and biological properties of newly identified versatile tacrine analogues and hybrids. We have also shown that these analogues may have therapeutic promise in the treatment of neurological diseases in a variety of experimental systems.

1. Introduction

Neurological disorders are very complex and multifaceted, necessitating multitarget medications that can cause multiple subpathologies at once. These illnesses are characterized by progressive failure of certain neurotransmitter system and the improper functioning of neural networks in the brain [1, 2]. There have been a growing number of studies undertaken to discover changes linked with neurological disorders, including in neurotransmitters, transporters, receptors, and metabolizing enzymes. Through nicotinic and muscarinic cholinergic receptors on monoaminergic
neurons, the cholinergic system can influence monoaminergic systems [3]. As a result, manipulating the cholinergic system can affect the signaling of other monoaminergic systems, and age-related changes in neurotransmitter systems can affect the response to such treatment techniques [4]. The use of small compounds to treat neurological disorders like Alzheimer’s disease (AD) by modulating cholinergic and glutamatergic neurotransmissions has been suggested. A powerful acetylcholinesterase inhibitor (AChE), tacrine, was the first medicine approved by the US Food and Drug Administration for the treatment of AD [5]. It is a low-affinity N-methyl-D-aspartate receptor (NMDAR) antagonist. In addition to being an AChE inhibitor, tacrine has been revealed to have a variety of cholinergic actions, including boosting the synthesis and release of acetylcholine (ACh) and modulating the muscarinic and nicotinic receptors. It has also been shown that tacrine interacts with monoaminergic systems. A number of investigations have suggested. A powerful acetylcholinesterase inhibitor (AChE), tacrine, was the first medicine approved by the US Food and Drug Administration for the treatment of AD [5]. It is a low-affinity N-methyl-D-aspartate receptor (NMDAR) antagonist. In addition to being an AChE inhibitor, tacrine has been revealed to have a variety of cholinergic actions, including boosting the synthesis and release of acetylcholine (ACh) and modulating the muscarinic and nicotinic receptors. It has also been shown that tacrine interacts with monoaminergic systems. A number of investigations have indicated that the memory-enhancing qualities of tacrine are more nuanced than previously thought. It has been shown to target a variety of pathways, including the theninergic, gamma-aminobutyric acid (GABA)ergic, glutamatergic, and AChE pathways [6–10].

Although tacrine was the first drug approved for the treatment of AD, it was banned in 2013 by US Food and Drug Administration (FDA) due to its toxic effects on liver. After the prohibition, most of the research focused on finding safer analogues and of tacrine and its complex with other hepatoprotective agents to treat AD in a multitarget-directed ligand approach. Tacrine has effect against neurological disorders in a molecular basis [11].

This article explains the therapeutic effect of tacrine, its analogues and derivatives discovered in several preclinical studies in a variety of neurological disorders, especially Alzheimer’s disease particularly from a pharmaceutical standpoint. Furthermore, this article includes an overview of tacrine and examines the molecular mechanistic role of tacrine effects against the neurological disorders.

2. Overview of Tacrine

Tacrine’s pharmacological actions were initially characterized by Shaw and Bently in 1946 [7, 12]. It was first used in clinical practice to treat anesthetic-induced delirium and to enhance the muscle-relaxing effects of succinylcholine [13]. It was first thought that tacrine would help counteract the respiratory depression caused by morphine; however, it was later revealed that it also acted as an inhibitor of both AChE and butyrylcholine esterase (BChE) [9, 14]. In 1993, tacrine became the first medicine to be licensed for the treatment of Alzheimer’s disease; however, its hepatotoxicity limited its usage [1]. Additional effects of tacrine have been discovered throughout time, including reduction of monoamine oxidase activity, inhibition of 5-hydroxytryptamine receptor and dopamine neuronal uptake, blockade of certain potassium ion channels, and interaction with muscarinic ACh receptors [15, 16].

Tacrine (9-amino-1,2,3,4-tetrahydroacridine, or THA) is an acridine containing three rings, but only a little substitu-

tion of an amino group in the fifth position is a white crystalline powder that dissolves in water, Tacrine’s pKa value is 9.85, and it has a planar chemical structure [7]. Though it is totally ionized at pH 7, it is likely that the positive charge is spread out between the mesomeric structures [16]. Tacrine is quickly absorbed and has a bioavailability between 10% and 30%. Absorption can be reduced by as much as 40% when taken with food. Plasma proteins account for approximately 55% of the binding of tacrine. Its clinical half-life is approximately 3–6 hours after a single oral dose. Oral tacrine has a therapeutic dosage range of ten-fold, necessitating individualized dosing. The distribution volume appears to be 182 liters. During the last elimination phase, the plasma half-life is 2.5 hours on an average [7]. It has been reported incorrectly that 1-OH-tacrine, a pharmacologically active form of tacrine, is formed during metabolism. In reality, tacrine is broken down into up to seven distinct compounds during digestion, which include dextro-chiral (stereospecific) version of 1-OH-tacrine [14, 17].

Multiple modes of action exist for tacrine. Tacrine’s primary mechanism of action in neurological disorders is as an acetylcholinesterase inhibitor that acts noncompetitively but selectively on the central nervous system (CNS). Moreover, CNS abnormalities extend beyond the cholinergic system and include serotonin neurotransmitter deficits, noradrenaline neurotransmitter deficits, and reduced vascular perfusion [18, 19]. Tacrine has some BChE selectivity over AChE. There are several other consequences on cholinergic system apart from enzyme inhibition: boost in production and secretion of ACh, activation of M1 subtype muscarinic receptors, suppression of M2 subtype muscarinic receptors and a raise in brain nicotinic receptors, and their potentialization at low and inhibition at high concentrations as well as a general potentiation of neuromuscular communication [20, 21]. Additionally, tacrine affects a wide range of biological targets, including neuromuscular junctions, potassium channels, sodium channels, and phosphorylation. Tacrine has been demonstrated to limit the absorption and increase 5-HT, noradrenaline, and GABA release; it also has an inhibitory action both monoamine oxidase (MAO)-A and MAO-B monoamine oxidase subtypes, and it suppresses brain histamine N-methyltransferase. As an example of this, tacrine has been demonstrated to reduce potassium-induced release of excitatory amino acids and block neuronal calcium channels in large dosages [21, 22].

In addition, tacrine was found to have a positive effect on ketamine side effects. It is mostly used to initiate and maintain anesthesia with the help of ketamine. Pseudo-hallucinations, delirium, and hypnagogic states were all common side effects of this medication’s treatment. Postoperatively, tacrine has been shown to reverse psychotic episodes. It was discovered that tacrine’s effects on the CNS were due to its interaction with adrenergic and cholinergic receptors [21, 23].

Pure anticholinesterase inhibitors like physostigmine and donepezil do not share two other peculiar properties of tacrine. An important benefit of tacrine in people with neurological disorders is that it greatly enhances cerebral blood flow. Decreased cerebral blood flow is linked to many neurological illnesses. Second, tacrine prevents the release of
β-precursor protein from the intestinal tract. There are numerous metabolites that can be formed by metabolism of tacrine by cytochrome P450 1A2 system. In the early stages of tacrine administration, the hepatocellular response that is typical of many pharmacological drugs can occur. It is not known if tacrine and/or its metabolites are excreted in the bile or if they are transported via the enterohepatic system. The clearance of tacrine, however, does not appear to be affected by renal impairment [9, 15, 21].

3. Tacrine Derivatives

Tacrine (9-amino-1,2,3,4-tetrahydroacridine) acts by three times more effectively inhibiting butyrylcholinesterase (BChE) than acetylcholinesterase (AChE). When the carbocyclic ring was modified from a cyclopentyl (compound (1)) to a cycloheptyl ring (compound (2)), the efficiency against BChE activity enhanced approximately 4-fold, while the efficacy against AChE activity increased 2-fold. On the other hand, the anticholinesterase activity of the cyclooctyl derivative (compound (3)) was 100 times lower than that of tacrine, presumably owing to the carbocyclic ring’s increased flexibility and bulk. The introduction of a methylene bridge in tacrine’s cyclohexyl ring (compound (4)) leads to a reduction in anticholinesterase efficacy (IC$_{50}$ against AChE: 0.24 μM) that further significantly improved while the substituent bulk on the bridge is increased by three methyl groups compound (5) (IC$_{50}$ against AChE: 110.0 μM). The inclusion of a fourth benzene ring led to a change in compounds with high AChE selectivity over BChE; just like in comparison to tacrine, compound (6) was extremely selective for AChE rather than BChE, with an IC$_{50}$ of 0.35 μM and 3.1 μM against AChE and BChE, respectively. Against BChE (IC$_{50}$: 6.7 μM), tetracyclic compound (7) was 50 times more powerful than AChE (IC$_{50}$: 391.1 μM) [24].

In addition to being more effective AChE inhibitors over tacrine, certain halogenated analogues have a greater affinity for AChE over BChE. Additional study has attempted at what emerges when a halogen atom is incorporated into the benzene ring of parent cyclopentyl analogue compound (1). The insertion of Cl at position 6, compound (10), elevated the strength by six fold; nevertheless, the 6F compound was equipotent with the parent cyclopentyl analogue. In aspects of selectivity against AChE being preferred over BChE (the B/A ratio), the 5Cl, 6Cl, 8Cl, 7F, and 8F derivatives, with B/A ratios of 4.1, 13, 3.8, 6.2, and 19, respectively, were the most selective compounds [25].

Leon et al. assessed the biological activity of new tacrine analogues possessing a heterocyclic ring moiety at position C-4, such as 2-thienyl, 3- or 4-pyridyl, and 2-(N-acetyl)-pyrrol groups. Among the pyrano[3,2-e]pyridines and pyrano[2,3-b]quinolines series, the pyrrolyl possessing molecule compound (8) is by far the most effective, with an IC$_{50}$ against AChE: 1.7 μM, approximately 10-fold decline in levels of activity in comparison to tacrine. Compound (9) was the most powerful of the [1,8]naphthyridine derivatives, with an IC$_{50}$ against AChE: 1.4 μM [26].

Friedländer-type reactions of 2-aminopyridine-3-carbonitriles with 1-benzyl-4-piperidone or cyclohexanone have yielded new tacrine analogues. The biological analysis demonstrated that, in nanomolar range, certain of these compounds were effective AChE inhibitors, as well as selective inhibitors of BChE. Compound (11) is the shortest N2-alkyl substituted compound, and it performs better than the molecules with longer alkyl chain. This inhibitor has an identical AChE inhibition profile (IC$_{50}$: 14 nM) as tacrine, even though it is a weaker BChE inhibitor (IC$_{50}$: 5.2 μM). The insertion of an electron-withdrawing substituent like Cl at C-2 contributed in a substantial reduction in anticholinesterase activity. Furthermore, to enhance AChE selectivity, an N-benzyl was substituted for the methylene group at C-7, as demonstrated in two instances: (i) from compound (13) to compound (15) and (ii) from compound (14) to compound (16). Meanwhile, inhibitor A was 5.8 times more effective against EeAChE (AChE from Electrophorus electricus) in relative to compound B; both of these compounds possess a methoxy group at C-2. Nonetheless inhibitor C was 14 times less powerful than inhibitor D against EeAChE, and both compounds included a chlorine atom at C-2 [27].

Tacrine is covalently bonded to some other pharmacologically active compounds, including such as a M1 agonist xanomeline and (Z)-3-(4-(chlorophenyl)-N-((4-chlorophenyl)sulfonyl))-N-methyl-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboximidine known as an antagonist of CB1 receptor, which enables to consolidate tacrine’s profound AChE inhibition with other pharmacological features [28]. The AChE inhibition of compound (17) is 1,000-fold broader than that of tacrine [29]. In respect to compound (17), compound (18) has a lower toxicity, yet will inhibit AChE and BChE in the same frequency as tacrine [28, 30].

Tang et al. created a variety of tacrine-o xoisoaporphine hybrids in their pursuit for more effective tacrine derivatives. In most instances, these compounds display significant AChE inhibitory potential, IC$_{50}$ values being in nanomolar range, with the most impactful AChE inhibitor reported being compound (20) (IC$_{50}$: 3.4 nM) [31].

Mao et al. discussed the design, synthesis, and assessment of a variety of o-amino benzylamine and o-hydroxyl tacrine hybrids, as well as o-hydroxyl benzylamine-(7-chlorotacrine) hybrids as multifunctional anti-AD drugs. Over these variants, compound (21) inhibits AChE (IC$_{50}$: 0.55 nM) more effectively than tacrine [32].

7-MEOTA (9-amino-7-methoxy-1,2,3,4-tetrahydroacridine), a new AChE inhibitor, was shown to be exempt of several toxicities particularly in comparison to tacrine (Figures 1 and 2). Korabecny et al. generated a number of 7-MEOTA analogues by alkylating the aromatic amino moiety of this new AChE inhibitor, with intriguing findings. C5–C9 chains outperformed their parent molecule 7-MEOTA and also in specific instance of inhibition of hAChE (human recombinant AChE), compound with a hexyl chain being the most effective (IC$_{50}$: 0.10 μM) [33].

4. Molecular Basis of Tacrine Derivatives’ Action against Neurological Disorders

4.1. Modulation of Neurogenesis. Animal and human brains undergo a process known as neurogenesis, in which new
nerve cells are continuously created throughout the life span of the organism. They are capable of differentiating into functional cells of the central nervous system and integrating into existing neural circuits in the brain after they have been born [6, 34]. Therapy for Alzheimer’s disease may be possible if neuronal regeneration (neurogenesis) is targeted in the

![Diagram of compounds of tacrine analogues.](image)

**Figure 1:** Illustration of compounds of tacrine analogues. The compound number denoted by (1) 9-Amino-2,3-dihydro-1H-cyclopenta[1,2-b]quinoline. (2) 11-Amino-2,3,4,5-tetrahydro-1H-cyclohepta[1,2-b]quinoline. (3) 12-Amino-1,2,3,4,5,6-hexahydrocycloocta[1,2-b]quinoline. (4) 9-Amino-1,4-methano-1,2,3,4-tetrahydroacridine. (5) 9-Amino-1,4-methano-1,2,3,4-tetrahydro-4,11,11-trimethylacridine. (6) 6-Amino-4,5-benzo-5H-cyclopenta[1,2-b]quinoline. (7) 9-Amino-5,6,7,8-tetrahydroquinolino[3,2-e]-1-benzocine. (8) Ethyl 4-(1-acetyl-1H-pyrrol-2-yl)-5-amino-6,7,8,9-tetrahydro-2-methyl-4H-pyran[2,3-b]quinoline-3-carboxylate. (9) Ethyl 5-amino-6,7,8,9-tetrahydro-2-methyl-4-[(4-pyridyl)-benzol[b][1-8]naphththyridine-3-carboxylate. (10) 9-amino-6-chloro-2,3-dihydro-[1H] cyclopenta [1,2-b]quinoline. (11) 5-Amino-2-(dimethylamino)-6,7,8,9-tetrahydrobenzo[1,8-b]-naphthyridine-3-carbonitrile. (12) 5-Amino-2-(prop-2-yn-1ylamino)-6,7,8,9-tetrahydrobenzo[1,8-b]-naphthyridine-3-carbonitrile. (13) 5-Amino-2-(methylxy)-6,7,8,9-tetrahydrobenzo[1,8-b]-naphthyridine-3-carbonitrile. (14) 5-Amino-2-chloro-6,7,8,9-tetrahydrobenzo[1,8-b]-naphthyridine-3-carbonitrile. (15) 5-Amino-7-benzyl-2-methoxy-6,7,8,9-tetrahydropyrido[2,3-b][1,6]naphthyridine-3-carbonitrile. (16) 5-Amino-7-benzyl-2-chloro-6,7,8,9-tetrahydropyrido[2,3-b][1,6]naphthyridine-3-carbonitrile. (17) Bis(7)tacrine dimer. (18) Cystamine-tacrine dimer. (19) Nontoxic tacrine-organic nitrates, compound E (as the name wasn’t found in the paper). (20) N-((7-Oxo-7H-dibenzo[de,h]quinolin-9-yl)-3-((2-((1,2,3,4-tetrahydroacridin-9-yl)amino)ethyl)amino)propanamide. (21) N1-(2-((Dimethylamino)benzyl)-N9-(1,2,3,4-tetrahydroacridin-9-yl)nonane-1,9-diamine. (22) N-alkyl-7-methoxytacrine.
hippocampus [35]. Subventricular zone (SVZ) and dentate gyrus (DG) of the hippocampus are two regions of the mammalian brain where neurogenesis continues into adulthood. When NPCs are multiplied in many locations, new neurons and glial cells can be generated in the brain [8, 36, 37]. With the help of the bromodeoxyuridine (BrdU)-labeling paradigm, Jin et al. determined the effects of tacrine on neurogenesis in adult mice. According to the findings, it increases neurogenesis in the DG and SVZ by 26–45%, although it has no effect on BrdU labeling in the DG [35]. In order to study the effects of compound (17), an acetylcholinesterase (AChE) inhibitor, on cognitive performance, neuronal apoptosis, and neurogenesis in the hippocampal region of adult male Sprague-Dawley rats, was permanently ligated of the bilateral common carotid arteries [38]. The neuroprotective effects of tacrine and its analogues have been proven in several investigations, including those by Li et al. and Luo et al. Tacrine and its analogues antagonize glutamate excitotoxicity...
and reduce neuronal nitric oxide synthase activity [39, 40]. Farkas et al. discovered that administering compound (17) to a chronic cerebral ischemia rat corrected the impairments in spatial learning and memory that had previously been seen. In the hippocampus, the neuroprotective impact of compound (17) may be exerted through the promotion of neurogenesis in the DG and the inhibition of apoptosis in the CA1 area, respectively. They observed that this impact could potentially be due to alteration of cholinergic receptors that are expressed on neural progenitors and that these receptors in turn may promote neurogenic factors [41].

4.2. Modulation of Neuroinflammation. The recognition of the role played by inflammation in the progression of a wide range of diseases has prompted innovative efforts to discover therapeutic approaches to reduce inflammation. Cholinergic deficiency and neuroinflammation are critical factors in both acute and long-term CNS disorders [2, 21, 42]. Glial cell activation (astrocytes and microglia) is a frequent feature of many neurodegenerative illnesses, and it is largely responsible for this process. Glial cells activated during brain inflammation may produce proinflammatory mediators, which have been linked to the neuropathology that produces cognitive impairments in neurological diseases [43, 44]. In neurodegenerative illnesses, the balance between proinflammatory and anti-inflammatory cytokines also has an impact on the course of the disease [15, 45]. According to Zhang et al., hippocampal injection of a tacrine analogue known as 4-(bis(pyridin-2-ylmethyl)amino)-N-((1,2,3,4-tetrahydropyridin-9-yl)amino)propyl)butanamide could effectively attenuate Aβ1-42 oligomers-induced cognitive dysfunction by activating the CREB/BDNF signaling pathway, decreasing tau phosphorylation [46]. According to the findings of a study conducted by Tyagi et al., tacrine may have an inhibitory effect on lipopolysaccharide (LPS)-induced neuroinflammation in adult Swiss albino mice, as evidenced by a decrease in the high levels of IL-2 in the brain [42]. Being AChEI inhibitors, tacrine and its analogues work by increasing the availability of acetylcholine in central cholinergic synapses and are hence considered as the most promising medications now available for the treatment of neurological diseases like AD [47, 48]. As per Jerábek et al., tacrine-resveratrol-fused hybrids have the potential to be exploited as multitargeted ligands against neurological diseases especially AD due to their fascinating anti-inflammatory and immunomodulatory capabilities in neuronal and glial AD cell models [49]. Moreover, in a cell-based experiment conducted by Alfadly et al., the antineuroinflammatory and neuroprotective characteristics of tacrine were demonstrated by a reduction in the expression of IL-1β and TNF-α, as well as the formation of ROS, in LPS-challenged PC12 cells following treatment with the chosen inhibitors [50]. Tacrine, as discovered by Xu and Xu, alleviated thermal hyperalgesia and mechanical allodynia following sciatic nerve chronic constriction injury while also restoring functional morphological damage in rats. Besides that, tacrine inhibited the growth and activation of glia and decreased IL-1, IL-6, and TNF-α level in the blood. Tacrine also had an anti-inflammatory effect on the JAK2/STAT3 signaling pathway, which is involved in neuroinflammatory processes. These findings suggest that tacrine may be a good option for use as an analgesic drug in the treatment of neuropathic pain [51].

4.3. Modulation of Endoplasmic Reticulum Stress. Inhibition of DNA synthesis by tacrine results in functional and structural alterations in the liver’s endoplasmic reticulum, ribosome, and mitochondria. As an acetylcholinesterase inhibitor (AChEI), tacrine has the potential to interfere with the normal trafficking of AChE in the endoplasmic reticulum (ER) [48, 52]. Tacrine exposure in neuronal cells with AChE (e.g., neurons) resulted in accumulation of misfolded AChE. Due to ER stress and the unfolded protein response’s downstream signaling cascade, this misfolded enzyme is incapable of moving to its target, resulting in neuronal death via apoptosis [7, 53]. ER-mitochondrial collaboration enhanced mitochondrial membrane potential loss when the stress level was too high. After a while, the tacrine-exposed cells were unable to maintain homeostasis any longer and eventually died. Tacrine promoted ER stress and apoptosis, which were inversely related to the concentration of AChE [9]. By causing ER stress in neurons, other AChEIs (rivastigmine and bis(3)-cognitin) could create the same problem as tacrine. Tacrine and other AChEIs interfere with AChE’s normal transport across the ER. Once neurons and other cells have been damaged, they die. AChEIs for the treatment of neurological disorders like AD may benefit from these findings, which can be used to guide the development of new drugs [10, 39, 54, 55]. Using cultured neuronal cells, Liu et al. found that tacrine disrupts oligomeric acetylcholinesterase’s ability to properly assemble, leading to endoplasmic reticulum–stressed death [54].

4.4. Modulation of Apoptosis. Apoptosis is a process in which cells actively participate in their own death. The regulation of apoptotic cell death can be regulated by a number of genes like bcl-2 family [56, 57]. Although the exact origin and mechanism of neuron death in neurological disorders like AD are still unknown, research suggests that oxidative stress may play a role. During neurodegeneration, reactive oxygen species (ROS) have been proposed to play a significant role in oxidative damage, which can be created by the cell lysis, by an excessive amount of free transition metals, or by an oxidative burst [7, 17]. Alzheimer’s disease patients’ brains appear to degenerate by an apoptotic process, including the presence of damaged DNA, nuclear apoptotic bodies, and other apoptosis-related markers in postmortem tissue samples. As a result of these findings, it is possible that apoptosis can be prevented or delayed by using ROS-inhibiting therapies, which may be a viable treatment option for the disease [58, 59].

Wang et al. reported that tacrine protects against H2O2-induced apoptosis, presumably by preventing the production of proapoptotic genes such as p53 and bax in the cells [58]. A tacrine analogue called as tacrine(2)-ferulic acid was found to inhibit 6-hydroxydopamine-induced apoptosis in rat pheochromocytoma (PC12) cells by activating the phosphoinositide 3-kinase (PI3-K)/Akt signaling pathway, according to the findings of Zhang et al. [57]. Gao et al. (2013 and 2014) reported that tacrine causes apoptosis, thereby imposing cytotoxicity in HepG2 (American Type
Culture Collection HB-8065) cells via a lysosome- and mitochondria-dependent mechanism and increased intracellular ROS production [17, 60]. Apoptosis has been linked to oxidative stress, and prior research has shown that tacrine, huperzine A, and donepezil protect against exogenous β-amyloid-induced damage and ameliorate redox disequilibrium in aged rats [56, 57, 61, 62]. Tacrine may be a helpful neuroprotective medication that lowers oxidative stress-induced cell death, which may complement its AChE inhibitory capabilities for the treatment of neurological illnesses. One of the hallmarks of apoptosis is oxidative stress, which has been linked to a wide range of cell death mechanisms and which in turn is triggered by ROS. YCG063 was tested as a ROS inhibitor by Gao et al., to see if it affected tacrine-induced apoptosis. The results show that YCG063 greatly suppresses tacrine-induced apoptosis, implying that tacrine-induced apoptosis is directly linked to ROS generation [17]. Apoptosis is triggered by tacrine, and ROS is a key player in this process. To put it another way, oxidative stress can lead to mitochondrial permeability transition (MPT) if ROS levels are greater than the cell’s capacity to deal with them, which in turn increases ROS levels and the stress [17, 60, 63].

AChE activation by tacrine and its analogues might also possibly play a crucial role in apoptosis, as suggested by various research studies [7, 26, 48, 64, 65]. Apoptosis was increased in retinal cells from chick embryos transfected with AChE sense vectors, and highly purified AChE proteins have been demonstrated to be harmful to cells via the apoptotic mechanism. These findings suggest that AChE is involved not only in mammalian organ development but also in regulating how well it can respond to external stimuli [57, 58]. These noncholinergic effects of AChE may be crucial in neurological disorders, and tacrine may be able to influence them positively [4, 7].

4.5. Role in Energy Metabolism. Alterations in cellular energy metabolism and mitochondrial dysfunction are two further aspects that contribute to the pathophysiology of neurological disorders [5, 66]. Multitarget-directed ligands combine cholinesterase inhibition with antioxidant capabilities to favorably alter neuronal energy metabolism and mitochondrial function to reduce illness symptoms [67–69]. The effect of ChE inhibitors (tacrine and 7-methoxytacrine) on the activity of mitochondrial complex I in the brain of a pig was investigated by Korábečný et al. and Hroudová et al., in mitochondria from the brain of the animal [70, 71]. Tacrine dramatically reduced the activity of mitochondrial complex I, which may result in tacrine-induced deleterious consequences associated with imbalances of electron transport chain [7, 72]. A disruption in the activity of complex I, which is critical in the regulation of oxidative phosphorylation, could result in impairment of cellular energy metabolism and, as a result, abnormalities in neuronal activity. As a result of inhibition of oxidative phosphorylation, glycolytic energy generation can become more prominent in tissues with high-energy requirements, such as the brain, which is especially true for the brain [71, 73]. Berson et al. reported that the weak base tacrine has a protonophoric action in mitochondria due to its high proton concentration.

When the cell’s energy expenditure increases without a concurrent increase in ATP production, the result is cell malfunction at low dosages and cell death at high levels, according to the literature. These mitochondrial effects are observable in cells from either rats or humans who have been treated to tacrine at clinically relevant concentrations or dosages [74].

4.6. Regulatory Role in Gene and Protein Expression. Tacrine regulates Kv2.1 channel gene expression and cell proliferation, according to Hu et al. [34]. Transcription factors have been shown to influence the expression of proapoptotic Bcl-2 and antiapoptotic Bax genes, respectively, in response to the p53 tumor suppressor gene [75]. In both developed and undifferentiated human neuroblastoma cell lines, Lahiri et al. found that tacrine altered the secretion of the β-amyloid precursor protein. Fu et al. found that compound (17) has been shown to be effective in protecting primary cultured astrocytes, pheochromocytoma cells, and neurons from hydrogen peroxide-induced apoptosis as well as against amyloid beta protein and glutamate-induced apoptosis. Tacrine derivatives accelerate human glioma SF295 cell death and change glioblastoma-related proteins such as p53, β-catenin, MAP2c, Iba-1, Olig-2, HLA-DR, and IDH1-proteins related to disease development [76]. ChAT and M3 and M5 muscarinic receptor subtypes downregulation in chronic hypoperfusion-induced cognitive deficits can be alleviated by tacrine therapy, according to the findings of Zhao et al. [77]. By protecting neurons against amyloid β protein-induced cell death and apoptosis, tacrine may serve as more than just an AChEI. It may also stimulate antiapoptotic gene expression by lowering oxygen-free radicals during neuronal injury [78]. Alfrevic et al. reported that tacrine-induced transaminitis was linked to genetic variations in ABCB4, which encodes the MDR3 phosphatidylcholine transporter. Tacrine does not appear to be a substrate or inhibitor of MDR3 [79].

4.7. Role in Ca²⁺ Homeostasis Modulation. Cell death can be controlled by calcium, which is a second messenger in the body. It has even been proposed that the final common mechanism for all types of cell death is Ca²⁺ overload [80]. The imbalance of Ca²⁺ in the body is now recognized as a common factor in the pathophysiology of Alzheimer’s disease [81]. Ca²⁺ has recently been linked to the toxicity and buildup of amyloid protein, which, in turn, shows collaboration with tau protein [82]. Since nimodipine, a well-known calcium channel blocker, and tacrine, a well-studied calcium channel blocker, have been combined structurally, Marco-Contelles et al. have produced tacripyrines, a new therapeutic candidate (lead drug candidate RL2/101) [83]. It has been demonstrated that RL2/101 interacts with the peripheral anionic site of AChE as well as the L-type of Ca²⁺ channels concomitantly. Several studies have shown that tacrine affects the homeostasis of Ca²⁺. Tacrine has been shown to inhibit high-threshold calcium currents by Kelly et al. [82] and Lermontova et al. [84]; however, their investigation required significantly larger concentrations of tacrine, and they were unable to identify the channels involved. Tacrine
had no effect on calcium levels in synaptosomes, according to Gibson et al. [85] and Marco-Contelles et al. [83]. Doležal et al. [86] showed that tacrine attenuates the influx of calcium by blocking L-type and N-type calcium channels in cholinergic SN56 neuronal cell lines. This inhibitory action is not a consequence of the AChE activity of tacrine. An important consideration in determining tacrine’s therapeutic potential is whether or not low micromolar concentrations of the drug interfere with calcium-dependent processes. Tacrine-dihydropyridine hybrids have a great neuroprotective profile and a modest blocking action on L-type voltage-dependent calcium channels due to the moderation of $[Ca^{2+}]$ elevation triggered by K⁺ depolarization. Chioua et al. found that blocking the entry of Ca²⁺ ions through L-type voltage-gated calcium channels by tacrine is a valuable strategy to prevent neuronal damage in neurological disorders like AD [73]. Tacrine treatment in male Crl:CD mice significantly increased the mitochondria’s vulnerability to calcium-induced mitochondrial permeability transition, according to Mansouri et al. [59].

### 4.8. Osmotic Regulation

Tacrine is structurally similar to 9-aminoacridine, which is an open Na⁺ channel blocker, as well as 4-aminopyridine, which is a K⁺ channel blocker. Several investigations have demonstrated that tacrine has a direct effect on Na⁺, K⁺, and Ca²⁺ channels [7]. Tacrine reduces Na⁺ currents at a rate that is much larger than K⁺ currents, according to Adem [87], who performed voltage clamp tests on myelinated axons. It was recently reported that THA-induced action potential lengthening is caused by a modification of cystamine, forming compound (18) (Figure 3). This dimer exhibited a lower toxicity and greater ability to act as cholinesterase inhibitor, against both AchE (acetylcholinesterase) and BchE (butyrylcholinesterase). It is also able to inhibit beta-amylloid aggregation and displays a neuroprotective action against oxidative injury induced by H₂O₂ on SH-SY5Y cell line. According to research, the chemical (18) exerts its neuroprotective effects through activating kinase 1 and 2 (ERK1/2) and the Akt/protein kinase B (PKB) pathways [92].

By synthesizing new multifunctional tacrine-trolox hybrids, which have both ChE inhibitory and potent antioxidant activities akin to the mother molecule, trolox, Xie, Lan et al. were able to create compounds with both of these features. Compound 6d was shown to be the most effective inhibitor of AChE in male Sprague-Dawley (SD) rats (IC₅₀ value of 9.8 nM for eeAChE and 23.5 nM for hAChE). A powerful inhibitor of BuChE was also found (IC₅₀ value of 22.2 nM for eqBuChE and 20.5 nM for hBuChE). Studies in molecular modeling and kinetics reveal that 6d is a mixed-nature inhibitor that binds to both the CAS and PAS regions of AChE concurrently. The hepatotoxicity of 6d was shown to be substantially lower than that of tacrine in in vivo tests.

### 5. Therapeutic Potential of Tacrine

#### 5.1. Alzheimer’s Disease

There are millions of older people throughout the world who are suffering with Alzheimer’s disease (AD), a debilitating and incurable neurological illness. The treatment options available currently only achieve some short-term relief from the cognitive symptoms. The major mechanisms of this disease include accumulation of amyloid beta (Aβ) proteins forming neurofibrillary tangles, loss of cholinergic activity, elevation of oxidative stress, and disruption of homeostasis of transition metal ions [90]. Tacrine was the first approved drug against Alzheimer’s disease which was approved by the FDA in 1993. It worked as an inhibitor of cholinesterase [91]. But due to its liver toxicity, it was discontinued in the USA in 2013. Since then, tacrine has been used as a lead compound and combined with numerous ligands to create multitarget-directed ligands (MTDLs) or drugs to combat against the multifactorial aspects of AD.

Homodimer of tacrine known as compound (17) is a potential lead compound of novel MTDLs. The heptamethylene linker of compound (17) was replaced with the structure of cystamine, forming compound (18) (Figure 3). This dimer inhibits AChE activity and protects against BchE (butyrylcholinesterase). It prevents acetylcholine from being degraded, therefore augmenting acetylcholine levels. The therapeutic utilization of tacrine for AD therapy has been halted due to its toxicity to the liver, incurred by an elevation in liver transaminase and a decline in liver albumin. Meanwhile, medications that regulate a single target may not be therapeutically successful in multifactorial disorders like Alzheimer’s. As a corollary, a number of medicines acting on various targets particular to multifactorial diseases have been derived. Multitargeted-directed ligands (MTDLs) are the term for those kinds of novel medications.
A neuroprotective impact as well as excellent BBB permeability was also demonstrated. Overall, 6d can be considered a multifunctional drug for the treatment of Alzheimer’s disease (AD) [93].

Xie, Wang, et al. designed, synthesized, and tested another class of new multitarget compounds against Alzheimer’s disease: tacrine-coumarin hybrids. Most of the substances studied have robust AChE and BuChE inhibitory activity, as well as clearly selective MAO-B inhibitory activity. Inhibition of AChE and BuChE by 14c (IC50 values for eAChE and 16.11 nM and 33.63 nM, respectively) and BuChE was observed in the produced compounds (IC50 values of 80.72 nM for eqBuChE and 112.72 nM for hBuChE). As a competitive inhibitor of MAO-B, 14c is an effective anti-AD multitargeted drug with increased CNS penetration and reduced cell toxicity [94].

In this study, Zha et al. developed and synthesized twenty-six new tacrine-benzofuran hybrids and investigated their antieffectivity Alzheimer’s in vitro on recombinant human AChE (hAChE) and BChE (hBChE) from human serum. Inhibiting human acetylcholinesterase at a subnanomolar level (IC50 = 0.86 nM) and suppressing both hBACE-1 activity (IC50 = 1.35 M) and aggregation of -amyloid (IC50 = 0.86 nM) (hAChE- and self-induced, 61.3 percent and 58.4 percent, respectively). Tests on scopolamine-treated ICR mice found that 2e significantly improved their performance and had no hepatotoxic effects [95].

Experiments using in-silico docking modeling chose a linker that best suited the bimodal drug’s interaction with the active site of acetylcholinesterase enzyme (AChE). It was shown that compounds 9d and 9l had the highest results for AChE inhibition and for preventing superoxide formation as well as A-induced cellular toxicity, respectively, when compared to all other compounds tested in this study [96].

Bis(7)tacrine, which has a heptamethylene connection between two tacrine units, seems to be the most intriguing tacrine homodimer. It has a greater IC50 value of 1.5 nM for AChE inhibition as well as A-induced cellular toxicity, respectively, when compared to all other compounds tested in this study [96].

Designing novel anti-AD-modifying drugs entails inhibiting BACE-1, an enzyme concerned for -amyloid peptide (Aβ) formation. Apparently, bis(7)tacrine has been reported to suppress BACE-1 with an IC50 of 7.5 μM. In Neuro2a APPswe cells, bis(7)tacrine reduced the quantities of both intracellular and secreted Aβ without affecting APP expression (Figure 3). Bis(7)tacrine, like other multifunctional tacrine compounds, reduced AChE-induced Aβ aggregation. The multifunctional nature of bis(7)tacrine for AD therapy was further emphasized by the fact that it blocked both KV1.2-encoded potassium channels and native delayed rectifier potassium channels like tacrine. Furthermore, bis(7)tacrine is an

Figure 3: Illustration representing the site of action of different tacrine derivatives in Alzheimer’s disease.
antagonist of the γ-aminobutyric acid type A (GABA$_A$) receptor, having an IC$_{50}$ of 6.28 μM. This observation leads to the inference that AChEIs with considerable GABA$_A$ receptor antagonism would be more effective for treating AD than simple AChE inhibition alone [7].

Heptylene-linked bis-(6-chloro) tacrine, another homodimeric congener, has a substantially higher potency, with an IC$_{50}$ of 0.07 nM. Heptylene-linked bis-(6-chloro)tacrine dimeric congener, has a substantially higher potency, with IC$_{50}$ values in the subnanomolar range and antioxidant activity in an ORAC assay. For instance, compound X1 was simultaneously noncompetitive and reversible AChE inhibitor and implies that the enzyme’s PAS may interact with it. In an oxygen radical absorbance capacity (ORAC) analysis, compound X1 demonstrated a high ability to lessen the quantity of reactive oxygen species (ROS), like one might predict given the inclusion of the ferulic moiety [98–101].

Hybrids of tacrine and melatonin were also developed as AD therapy drugs with several functions. Melatonin was considered owing to its potential to neutralize a wide range of ROS in the body. It moreover promotes the activity of endogenous antioxidant enzymes, protects against Aβ, and suppresses neurofilament hyperphosphorylation. The most powerful AChEIs in this series, with IC$_{50}$ values in the subnanomolar range and antioxidant activity in an ORAC experiment, were X2 and X3. Comparing to propidium, compound X3 suppressed the self-promoted aggregation of the Aβ (63% at 10 μM). It has a 16.2% neuroprotection against Aβ$_{25-35}$ at 1 μM as well as cell viability of 100% at 1 μM and 80% at 10 μM. Furthermore, in neuroblastoma cells, X3 reduced rotenone-induced oxidative damage by 30% at 3 μM. Rotenone acts as an apoptosis inducer and suppresses mitochondrial complex I specifically [102, 103].

NO enhances blood flow and minimizes inflammatory responses, while both of which may be pharmacologically advantageous for Alzheimer’s patients. On this premise, tacrine was coupled to a NO donor unit using a suitable alkyle-diamine spacer. The antioxidant characteristics of ferulic acid, along with its neuroprotective efficacy against Aβ$_{25-35}$ toxicity in both in vitro and in vivo experiments, prompted the selection of this compound. It was found that compound X1 was simultaneously noncompetitive and reversible AChEI and implies that the enzyme’s PAS may interact with it. In an oxygen radical absorbance capacity (ORAC) analysis, compound X1 demonstrated a high ability to lessen the quantity of reactive oxygen species (ROS), like one might predict given the inclusion of the ferulic moiety [98–101].

Hybrids of tacrine and melatonin were also developed as AD therapy drugs with several functions. Melatonin was considered owing to its potential to neutralize a wide range of ROS in the body. It moreover promotes the activity of endogenous antioxidant enzymes, protects against Aβ, and suppresses neurofilament hyperphosphorylation. The most powerful AChEIs in this series, with IC$_{50}$ values in the subnanomolar range and antioxidant activity in an ORAC experiment, were X2 and X3. Comparing to propidium, compound X3 suppressed the self-promoted aggregation of the Aβ (63% at 10 μM). It has a 16.2% neuroprotection against Aβ$_{25-35}$ at 1 μM as well as cell viability of 100% at 1 μM and 80% at 10 μM. Furthermore, in neuroblastoma cells, X3 reduced rotenone-induced oxidative damage by 30% at 3 μM. Rotenone acts as an apoptosis inducer and suppresses mitochondrial complex I specifically [102, 103].

NO enhances blood flow and minimizes inflammatory responses, while both of which may be pharmacologically advantageous for Alzheimer’s patients. On this premise, tacrine was coupled to a NO donor unit using a suitable alkyle-diamine spacer to generate novel tacrine heterodimers. In vitro study using PGF2-preconstricted porcine pulmonary arteries demonstrates NO donor unit’s vasorelaxing properties. X4 was the most powerful of the heterodimers studied, with an EC$_{50}$ of 8.80 μM, whereas isosorbide dinitrate as a positive control had an EC$_{50}$ of 0.42 μM and tacrine as a negative control had an EC$_{50}$ of 97.3 μM. Unlike tacrine, X4 seemed to have no consequence of hepatotoxicity, since albumin, lactate dehydrogenase (LDH), and aspartate aminotransferase (ASAT) levels were unaffected by this heterodimer. Interestingly, in behavioral tests, X4 showed a significantly greater capacity to manage scopolamine-induced memory impairment compared to tacrine [104].

In order to target both the AChE and the muscarinic M$_2$ receptor allosteric site, tacrine-gallamine heterodimers were generated. This is because tacrine additionally functions as an allosteric modulator for muscarinic receptors, while gallamine blocks the AChE PAS and acts as a selective allosteric modulator for muscarinic M$_2$ receptor subtypes. X5 was the most powerful AChEI of the heterodimers studied in this series, with an IC$_{50}$ of 5.44 nM. Gallamine-tacrine heterodimers slowed [3H]N-methyl scopolamine dissociation, particularly X6 with an EC$_{50}$ value of 0.9 nM outperforms tacrine and gallamine by 4800 and 100 times, respectively. The ability of X6 to bind concurrently with the core and peripheral portions of the muscarinic M$_2$ receptor allosteric site might explain this augmentation in efficiency [105, 106].

Tacrine-donepezil heterodimers were generated by substituting donepezil’s benzyl moiety with tacrine connected with a polymethylene spacer. With an IC$_{50}$ value of 0.27 nM, X7 was found to be the most powerful AChEI. The AChE-induced Aβ aggregation was suppressed by X7 and X8, by 46.1% and 65.9% at 100 μM, hence demonstrating their interaction with the AChE PAS and their possible involvement in modulating AD pathology [107].

Among tacrine-propidium heterodimers, one of the balanced and intriguing compounds is X9. It decreased AChE-induced Aβ aggregation by 45.7% at 100 μM and modestly inhibited Aβ$_{1-42}$ aggregation, according to molecular modeling studies. Furthermore, this molecule blocked BACE-1 and was demonstrated to pass the blood-brain barrier, allowing it to approach its therapeutic targets in the CNS [7].

Tacripyrines, a new class of hybrid compounds, were developed by combining the calcium antagonist 1,4-dihydropyridine (DHP) skeleton with the tacrine in order to suppress AChE while also suspending L-type Ca$^{2+}$ channels. Cell death happens as a consequence of excess Ca$^{2+}$ influx via L-type Ca$^{2+}$ channels. In Alzheimer’s disease, Ca$^{2+}$ dysfunction promotes tau hyperphosphorylation and Aβ production [7]. Compound X10 was found to be the most promising because of its ability to inhibit hAChE with an IC$_{50}$ of 105 nM, as well as 34.9% moderate inhibition of self-aggregation of Aβ and 30.7% inhibition of AChE-induced Aβ aggregation [108]. Furthermore, it is enriched with the capability to block Ca$^{2+}$ (albeit lower than nimodipine) and to protect the brain from oxidative stress. It also inhibits AChE-induced Ab aggregation and may penetrate the BBB, as shown by an in vitro BBB permeability experiment [7]. Furthermore, X10 was revealed to be as effective as 3-[(benzylmethylamino)methyl]phenyl]-6,7-dimethoxy-2H-2-chromene (AP2238) and even more powerful than donepezil [108].

The PyridoTacrine family, which possesses the 1,8-naphthyridine motif, exhibits increased ChE inhibition and reduced hepatotoxicity while losing VGCC blocking efficacy. X11 is an MTDL for Alzheimer’s disease since it offers pharmacological activity against 2 different therapeutic targets related to neurodegeneration: ChE and PP2A. In animal models of AD and stroke, this compound demonstrated its therapeutic potential. In fact, when compared to BuChE, tacrine derivative X11 is a more powerful and selective AChEI. By activating PP2A, it may be shielding against glutamate-induced excitotoxicity. PP2A inhibition causes
tau hyperphosphorylation, which culminates in the generation of neurofibrillary tangles inside neurons, one of the most prominent indications of Alzheimer’s disease. PyrTac X11 lowers scopolamine-induced memory impairment, which might be encouraging outcomes for therapeutic application [2].

A tacripyrimidine series was generated by merging tacrine and 3,4-dihydroyrimidin-2(1H)-thiones. Concerning the biological profile of tacripyrimidines, compound X12 appeared as the well-balanced cholinesterase inhibitor and calcium channel blocker, with an IC50 value of 0.35 μM against hAChE and 3.19 μM against hBChE. This compound had modest calcium channel blocking activity of 30.4% at 1 μM; further, it did not cause any toxicity to HepG2 cells. X13 inhibits hAChE 10 times more effectively than tacrine, the strongest AChEI in the tacripyrimidine family. On the basis of hBChE inhibition, X14 was the most effective with an IC50 of 0.372 μM. In the test of Ca2+ channel blocking activity in SH-SY5Y neuroblastoma cells, X15 is the most strong, inhibiting 59.01%, followed by X16, which inhibited 66.79%, and the reference compound, nimodipine, which inhibited 49.62% [73].

Vilazodone and tacrine were combined to create a novel class of hybrid molecules for the treatment of depression associated with Alzheimer’s disease. Additionally, vilazodone is an inhibitor of 5-HT reuptake and a 5-HT1A receptor partial agonist. Serotonin deficiency has been linked to a number of mental disorders, including depression. Compound IC50 values for acetylcholinesterase inhibition (3.319 M), 5-HT reuptake inhibition (76.3 nM), and 5-HT1A agonist (EC50 = 107 nM) were all within a reasonable range for 3-(4-(4-(2,3-dihydro-1H-cyclopenta[b]quinoline-9-yl)piperazin-1-yl)butyl). It also significantly reduced hERG activity, exhibited tolerable hepatotoxicity, and could pass the blood-brain barrier in vivo. Cycle length has an effect on activity, which can be seen when the cycle size reduces: cycloheptane ring > cyclohexane ring > cyclopentane ring > no ring. The 5-HT1A antagonist’s action increases as the cycle length lowers. Adding the naphthenic ring to 5-HT reuptake inhibitory activity resulted in a significant increase in potency. 3 (Butyl)-1H indole-5-carbonitrile-HCl was found to considerably boost cognitive function and reduce depressive features in mice [109].

Among all benzochromenoquinolinones, 14-amino-13-(3-nitrophenyl)-3,4-dihydro-1H-benzo[6,7]chromeno[2,3-b]quinoline-7,12(2H,13H)-dione had the most suppressive activities on the cholinesterase enzyme. This chemical inhibited AChE with an IC50 of 0.86 μM and BChE with IC50 of 6.03 μM. Additionally, the IC50 value of this compound for BACE1 inhibition was found to be 19.60 μM. It is capable of binding to both the PAS and CAS sites found on AChE and BChE. Considering they possess the suitable biological attributes and have a minimal hepatotoxicity, benzochromenoquinolinones have evolved as a flexible anti-AD drug [110].

A chloro substitution of tacrine and several of its analogues has been effective in managing the ChEI action in the hunt for powerful AChEIs with minimal hepatotoxicity for the cure of Alzheimer’s disease. Adding chlorine atom to tacrine’s phenyl ring generated chlorinated tetrahydroacrinedines (THA) with considerable AChE inhibition. Furthermore, 3-cyano-2-substituted tetrahydroquinolines bearing a phenyl ring at the 4-position are also notable chlorinated analogues. When the 2-position of the pyridine ring had a chlorine atom added to it, this indicated the compound to be more efficacious than tacrine in inhibiting AChEIs while also being less harmful to the liver. The chlorinated 4-phenyltetrahydroquinolines have improved AChE inhibitory potential and minimal hepatotoxicity compared with the unchlorinated analogues. In addition to this, compound 4-(pchlorophenyl)pyrazolo[3,4-b]tetrahydroquinoline showed encouraging activity, and its formation requires joining the pyridine ring with the pyrazolo nucleus. In addition, this compound was depicted to being completely risk-free [111].

Within the central nervous systems of mammals, glutamate is one of the most prominent excitatory neurotransmitters. Glutamate excitotoxicity, which is accountable for neurodegeneration in ischemic and traumatic brain damage, is triggered by an overstimulation of postsynaptic glutamate receptors, specifically NMDA subtype. Evidence shows that mitochondrial dysfunction is a key and initial mechanism in glutamate excitotoxicity. In terms of reducing glutamate-induced excitotoxicity, posttreatment with compound (17) is much more effective than posttreatment with NG-nomethyl-L-arginine. Compound (17) posttreatment may reduce glutamate excitotoxicity by blocking signaling pathways of mitochondrion apoptosis, while preserving proper mitochondrial performance. Besides these qualities, compound (17) suppresses glutamate-induced oxidative stress and NOS activity. Thus, this tacrine homodimer might pave the way for a new approach for curing neurodegenerative disorders [112].

In terms of hindering DMPP-mediated Ca2+ uptake, the novel tacrine derivatives were quite far highly effective and powerful. Compounds X19 and ethyl 5-amino-6,7,8,9-tetrahydro-4-(m-methoxyphenyl)-2-methylpyrano[2,3-b]quinoxoline-3-carboxylate were the most efficient blockers, inhibiting 90% and 88.5% of DMPP-stimulated Ca2+ entry, respectively. On the basis of animal studies, compound X20 has the most effective Ca2+-blocking efficacy (IC50 0.3 μM) in comparison to the commonly used L-type Ca2+ channel blocker, diltiazem (IC50 0.03 μM) [113].

Besides, tacrine forms hybrid molecules other many other compounds, such as 7-hydroxycoumarin, ferulic acid, acidine, cinnamic acid, phenolic acid, hydroxyphenyl benzimidazole, tryptophan, and indoles, which possess potential therapeutic activity against Alzheimer’s disease (Table 1).

5.2. Parkinson’s Disease. Parkinson’s disease is caused by a decrease in the number of dopaminergic neurons in the substantia nigra portion of the brain. The presence and buildup of alpha-synuclein protein are the key pathological characteristic of Parkinson’s disease. Due to the excessive buildup, levels of dopamine begin to decline over time, leading to a range of motor and nonmotor disorder. It can be treated but not cured completely. For the purpose of treating Parkinson’s disease, a number of multifunctional targeted 3-arylcoumarin-tetracyclic tacrine derivatives were developed. Compounds X17 and X18 were shown to reduce
Table 1: Experimental findings on the use of tacrine derivatives in neurological disorders.

| Types of compound | Type of study | Study models | Dose/concentration | Assay type | Findings/activity | References |
|------------------|--------------|--------------|--------------------|------------|------------------|------------|
| Tacrine-benzoate (phenyl acetates or cinnamates) hybrid | In-vitro | AChE, from electric eel, BuChE, from equine serum | 5.63 nM | Ellman method | Inhibit AChE with highest selectivity ratio against BuChE | [114] |
| 7-MEOTA-donepezil-like hybrids | In-vivo | Male Wistar rats | 25.6, 12.3, 5.7, 5.2 mg/kg | Water maze test, passive avoidance test | Significant effect of the swim order indicating maintenance of learning ability | [115] |
| Tacrine-ferulic acid hybrids | In-vitro | AChE BuChE | 61.7 ± 5.2 106.9 ± 13.1 | Spectrophotometric method | Good inhibitory activity to both AChE and BuChE, better selectivity for AChE compared with tacrine | [100] |
| Ferulic acid-tacrine-melatonin hybrids (FATMHs) | In-vitro | SH-SY5Y cells | 1 μM and 3 μM | Neuroprotection analyses | Significant neuroprotection was observed against all toxic insults assayed | [116] |
| Tacrine-trolox, tryptoline hybrids | In-vitro | TcAChE from electric eel, eqBuChE (from equine serum) | 49.31 nM 17.37 nM | Ellman’s assay | Hybrids with longer linker chain lengths show increased AChE inhibitory activities compared to the shorter ones | [117] |
| Tacrine-cinnamic acid hybrids | In vivo | Adult ICR mice | 15 mg/kg | Morris water Maze test | Considerably ameliorated the cognitive impairment of the treated mice And was much better than tacrine | [118] |
| (Benz)imidazopyridino tacrines | In-vitro | AChE BuChE, Aβ (1–42) ICR mice | 10.2 nM 6.3 nM 30 mg/kg | Ellman’s Assay Thioflavin T-based fluorometric assay Morris water Maze test | Did not show any hepatotoxicity at all the time points Cholinesterase inhibitory activities, amelioration of scopolamine-induced cognition impairment, preliminary safety in hepatotoxicity evaluation | [119] |
| Tacrine-O-protected phenolics heterodimers | In-vitro | TcAChE from electric eel, eqBuChE (from equine serum) | 0.50 ± 0.03 μM | Ellman protocol | Nonhepatotoxic shows moderate and selective EeAChE inhibition | [120] |
| Tacrine-resveratrol-fused hybrids | In-vitro | AChE, from electric eel, BuChE, from equine serum | 3.5 μM | Ellman method | Safe, nonhepatotoxic, potent, and selective inhibitor of hBuChE | [121] |
| | | AChE, from electric eel, BuChE, from equine serum | 8.8 μM | Ellman method | AChE inhibition, Aβ self-aggregation modulation, anti-inflammatory, and immunomodulatory properties, high-predicted blood-brain barrier permeability, and low cytotoxicity | [49] |
| Types of compound              | Type of study | Study models                                      | Dose/concentration | Assay type                       | Findings/activity                                                                 | References |
|-------------------------------|---------------|--------------------------------------------------|--------------------|----------------------------------|-----------------------------------------------------------------------------------|------------|
| Tacrine-ferulic acid hybrids  | *In-vitro*    | Aβ (1–42)                                        | 20 μM              | Thioflavin T-based fluorometric assay | Inhibited amyloid β-protein self-aggregation by 65.49%                             | [122]      |
|                               | *In-vitro*    | AChE, from electric eel, BuChE, from equine serum| 37.02 nM           | Ellman method                    | Potent inhibitor against AChE and strong inhibitor against BuChE                  | [122]      |
|                               | *In vivo*     | Adult ICR mice                                   | 30 mg/kg           | Morris water maze test, serum ALT, AST test | Ameliorated the cognition impairment and showed preliminary safety in hepatotoxicity evaluation | [122]      |
| Tacrine-acridine hybrids      | *In-vitro*    | AChE, from electric eel, BuChE, from equine serum| 7.6 pM 1.7 pM      | Ellman method                    | More active inhibitor than tacrine                                               | [123]      |
|                               | *In-vitro*    | Aβ (1–42)                                        | 50 μM              | Thioflavin T (ThT) fluorescence assay | 54.74% inhibition of Aβ aggregation                                                 | [123]      |
| Tacrine-deferiprone hybrids   | *In-vitro*    | AChE, from electric eel                          | 0.64 μM            | Ellman method                    | Control of cholinergic dysfunction, amyloid peptide aggregation, oxidative stress, and metal modulation | [124]      |
| Tacrine, phenolic acid, and ligustrazine hybrids | *In-vitro* | AChE, from electric eel                          | 3.9 nM             | Ellman method                    | Potent inhibition activity towards cholinesterases (ChEs)                        | [125]      |
|                               | *In-vitro*    | —                                                | 85.8 ± 3.5 μM      | DPPH assay                       | Very potent peroxyl radical scavenging capacity                                 | [125]      |
| Cystamine-tacrine dimer       | *In-vitro*    | SH-SY5Y cell line                                | 0.005-0.5 μM       | MTT assay                        | AChE and BChE inhibitor; activates kinase 1 and 2 (ERK1/2) and Akt/(PKB) pathways | [92]       |
|                               | *In-vitro*    | Male Sprague-Dawley (SD) rats                    | 6 mmol/100 g b. wt  | (AST) and (ALT) activity         | Introduction of trolox could reduce the hepatotoxicity of tacrine                 | [93]       |
|                               | *In-vitro*    | Electric eel, Ellman’s reagent, DTNB              | 9.8-23.5 nM        | Ellman’s assay                    | Inhibitor against AChE and BuChE                                                | [93]       |
|                               | *In-vitro*    | PC12 cells                                        | 20.5-22.2 nM       | Ellman’s assay                    | More potent inhibitory activity for BuChE than for AChE                          | [93]       |
|                               | *In-vitro*    | Human neuroblastoma cell line, SH-SY5Y           | 3.125 μM and 6.25 μM | MTT assay                        | Significantly inhibit cell death                                                  | [93]       |
| Tacrine-propargylamine        | *In-vitro*    | Human neuroblastoma cell line, SH-SY5Y           | 10, 50, and 100 μM | MTT assay                        | Nearly no effect on the viability of SH-SY5Y cells, lower cytotoxicity than tacrine | [126]      |
| Types of compound                  | Type of study | Study models                        | Dose/concentration | Assay type          | Findings/activity                                                                 | References |
|-----------------------------------|---------------|-------------------------------------|--------------------|---------------------|-----------------------------------------------------------------------------------|------------|
| Tacrine-coumarin hybrids          | In-vitro      | hMAO-A, hMAO-B                       | 0.24 μM            | Fluorimetric method  | Selective MAO-B inhibitor                                                        | [94]       |
|                                   | In-vitro      | eeAChE, hBuChE                       | 16.11 ± 0.09 nM    | Ellman’s method     | Potent inhibitory action for AChE and BuChE                                       | [94]       |
|                                   | In-silo       | Recombinant hAChE                    | —                  | —                   | Simultaneously bind to PAS and CAS and the mid-gorge site of AChE                   | [94]       |
|                                   | In-vitro      | hAChE, hBuChE                        | 38 nM 63 nM        | Ellman’s method     | Potent and selective inhibitory activities towards both hAChE and hBuChE          | [127]      |
|                                   | In-vitro      | A-β1-40 peptide                     | 1 μM               | Thioflavin T assay  | Inhibit A-β40 amyloid self-assembly                                               | [127]      |
|                                   | In-silo       | Recombinant hAChE(1ACJ), hBuChE(4 BDS), β-secretase (BACE1) | — | AutoDock 4.2 and Vina | Fingerprints studies showed 34 ligands to be effective in their docking binding energies and high binding natures | [128] |
| Tacrine-benzofuran hybrids        | In-vitro      | Recombinant hAChE and hBChE         | 0.86 nM 1.35 μM    | Ellman’s assay      | Selectively inhibited hAChE, suppressed both hBACE-1 activity and β-amloid aggregation | [95]       |
|                                   | In-vivo       | ICR mice                            | 20 μmol/kg         | Morris water maze test | Considerably ameliorated the cognition impairment of the treated mice              | [95]       |
| Tacrine/cysteine-conjugated compounds | In-vitro     | Amyloid-β peptide                   | 70 μM              | Fluorescence assay  | Decreased Aβ42 (40 μM) self-aggregation                                             | [96]       |
|                                   | In-vitro      | Human neuroblastoma SH-SY5Y cells   | 2.5 μM             | MTT assay           | Cell viability is not significantly affected after a 24-h treatment                | [96]       |
|                                   | In-silo       | TcAChE                              | 0.30 μM            | Ellman0ts assay     | High inhibitory activity in submicromolar range                                    | [96]       |
|                                   | —             | —                                   | —                  | Molecular docking   | Target both the CAS and PAS of AChE                                               | [96]       |
| Tacrine-phenylbenzothiazole hybrids | In-vitro     | AChE from electric cel Aβ (1–42)    | 0.15 μM 40 μM      | Modified method of Ellman’s assay Thioflavin T (ThT) assay | Excellent AChE inhibitory activity and moderate inhibition values for amyloid-β (Aβ) self-aggregation (27–44.6%) | [129] |
| Tacrine-1,2,4-thiadiazole derivatives conjugates | In-vitro | Human erythrocytes AChE equine serum BChE, porcine liver CES | 17.1 μM 44.8 μM | Ellman method | Effectively inhibited cholinesterases with a predominant effect on (BChE), could block AChE-induced β-amyloid aggregation | [130] |
TnFA has been proven to reduce the symptoms of the condition. Be lessened by the dimer of tacrine (2)-ferulic acid, which 6-OHDA-induced Parkinson's disease cannot be treated with tacrine alone. 6-ODHDA caused cell death in PC12 cells. T2FA (20 M) lowered the frequency of cells with apoptotic bodies and nuclear condensation, decreased intracellular ROS, blocked GSK3β activation, and reversed the inhibition of the PI3-K/Akt pathway produced by 6-OHDA. Researchers found that T2FA, an AChE inhibitor, reduced 6-OHDA-induced apoptosis in PC12 cells and so might be used to change the etiology of Parkinson's disease (PD) [57].

5.3. Ischemia. Tacrine has no therapeutic activity against cerebral ischemia. But a dimer of tacrine, compound (17) and has shown notable activities against cerebral ischemia according to a few studies. Comparable to memantine, a well-known NMDA receptor antagonist used to treat Alzheimer's disease, compound (17) has promising properties on blocking the NMDA receptor. For this reason, the ability of compound (17) to impede focal cerebral ischemic injury in rats with middle cerebral artery occlusion was examined. The results showed that compound (17) (0.1-0.2 mg/kg) could notably decrease the neurological problems and improve the neurological score and reduced infarction and brain edema after 2-h occlusion/2411 reperfusion. The neuroprotective activity of compound (17) was almost 260 times higher than that of memantine. So compound (17) could be useful as a neuroprotective agent for treating stroke as it can reduce neurological consequences of ischemic injury by NMDA receptor inhibition [139].

In another experiment, the influence of compound (17) on apoptosis caused by ischemia in astrocytes of mice cerebral cortex was examined. The astrocyte cell cultures were incubated in ischemic condition for 6 hours, and lactate dehydrogenase (LDH) release assay showed significant reduction in

| Types of compound | Type of study | Study models | Dose/ concentration | Assay type | Findings/activity | References |
|-------------------|--------------|--------------|---------------------|------------|------------------|------------|
| Tacrine-hydroxamate derivatives | In-vitro | AChE BChE HDAC | 0.12 nM 361.52 nM 0.23 nM | Ellman method Fluorescence assay | Potent and selective inhibition on ache, potent inhibition on HDAC, recognition impairments inhibitory activity on Aβ1-42 self-aggregation as well as disaggregation activity on preformed Aβ fibrils | [47] |
| Tacrine-pyrimidone hybrids | In-vitro | Murine AChE Recombinant human GSK-3β | 51.1 nM 89.3 nM | Ellman’s method with modification | Possessed excellent dual AChE/GSK-3 inhibition both in terms of potency and equilibrium | [48] |
| | In-vivo | Female ICR mice | 15 mg/kg | Morris water maze (MWM) tests | Displayed significant amelioration on cognitive deficits in scopolamine-induced amnesia mice | [48] |
| Tacrine(10)-hupyridone dimer | In-vivo | Wild-type (WT) mice | 0.36 or 0.72 μmol/kg | Morris water maze (MWM) tests | Long-term treatment of the compound could attenuate precognitive impairments in APP/PS1 transgenic mice | [131] |
| Tacrine and salicylamide conjugates | In-vitro | AChE BChE | 0.22 μM 0.01 μM | Propidium iodide fluorescence | Exhibited high dual anticholinesterase activity with selectivity towards BChE | [132] |
viable cells’ percentage. Also, bisbenzimide staining determined that the anaerobic chamber caused apoptosis of 65% of the cells. During the ischemic incubation, the treatment with 1-10 nM concentration of compound (17) prevented this apoptosis of cells caused by oxygen deficiency, which was confirmed by both biochemical and morphological tests. So this drug can be beneficial against vascular dementia, which is caused by ischemia-induced death of the astrocytes [140].

Sprague-Dawley rats were used in another investigation to test the in vivo effects of compound (17) against localized cerebral ischemic injury. There was ischemia in the brain for 2 hours and 24 hours, and compound (17) was administered intraperitoneally after 15 minutes of this time period. Depending on the dose, the neurological abnormalities were improved, and both edema and cerebral infarct volume were decreased. It was shown is TUNEL staining assay that compound (17) reduced apoptosis of the neurons of penumbral region. The therapeutic window of compound (17) lasted until 6 hours which was wider than a similar NMDA receptor blocker memantine. But it did not change the blood flow of cerebral regions or any physiological variables in any stage of the experiment. So it can be concluded that the dose- and time-dependent effects of compound (17) can give protection against acute focal cerebral ischemic injury, probably through its antiapoptotic activity during numerous stages of the ischemic cascade [141].

Shu et al. stated that compound (17) at the dose of 0.2 mg/kg shortened the escape latency of adult male Sprague-Dawley rats whose spatial learning ability was impaired by chronic cerebral ischemia. Compound (17) lowered the rate of neuronal apoptosis in CA1 region of the hippocampus and enhanced neurogenesis in that region, compared to the saline-treated rats, as shown by immunohistochemical assay. Thus, it was suggested that compound (17) inhibits apoptosis and promotes neurogenesis in 2VO rats to exert its neuroprotective effects [38].

The neuroprotective impact of compound (17) on ischemia retinal injury was substantial. Compound (17) further prevented the reduction of amplitude of a- and b-wave in electroretinography, caused by ischemia. Ischemic damage led to a rise in the protein quantities of p53, which is a tumor suppressor gene well-known for its ability to trigger...
apoptosis. In such scenario, compound (17) therapy lowered the protein’s expression. The treatment with compound (17) offered protection from damages of acute focal cerebral ischemia. Furthermore, glutamate excitotoxicity in the extracellular space of the retina is hypothesized to be one of the processes underlying neuronal cell death in glaucoma. Compound (17) outperformed memantine in glutamate-induced neurotoxicity in rats by specifically inhibiting the NMDA-activated current. In addition, compound (17) has the ability to inhibit the formation of NO which is induced by glutamate. As a corollary, compound (17) may hold promise as a neuroprotectant therapeutic agent for the treatment of glaucoma [142].

6. Concluding Remarks

This study provided a concise summary of the existing understanding about tacrine analogues that have genuinely valuable therapeutic effects. This article reviews the literature in the fields of medicinal chemistry, pharmacology, and biology pertaining to the topic. The authors described NO-donor-tacrine hybrids that displayed hepatoprotective features, as well as fused with natural components that protect cells from oxidative damage, such as melatonin, hydroxyquinolone, or thioflavine. Additionally, addresses a broad range of hybrid compounds that were developed by researching into the pharmacophores of currently marketed drugs. Other examples of hybrid compounds that were developed by studying the pharmacophore of commercial medications have been described. Structured hybrid inhibitors of cholinesterases have effectiveness in inhibiting cholinesterases activity, as well as antioxidant capacity and the ability to prevent aggregation Aβ (β-amyloid). As a result, these compounds have the potential to operate as neuroprotective medications while also displaying increased biological activity. The currently targetable pathways have been outlined in detail in order to facilitate the development of neurotherapeutic drugs. The article provides a concise update as well as their viewpoint on actual and possibly druggable pharmacological targets for the illness of the central nervous system.

This review highlighted a number of innovative multitarget-directed tacrine analogues that have been developed to date and are categorized based on their biological target and chemical composition. Novel therapeutic prototype candidates have been uncovered, and several are already undergoing preclinical testing. It is the starting point for a radical shift in how we approach medication development. System biology may help medical scientists uncover novel chemical entities capable of comprehending and efficiently modifying this severe neurodegenerative condition, despite the fact that none of these MTDL medication candidates has reached the clinical stage.

Data Availability

All data used to support the findings of this study are included within the article.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

This publication was supported by the Deanship of Scientific Research at Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia, as well as the authors are sincerely grateful to Egyptian Russian University, Badr, Egypt.

References

[1] P. Szymański, R. Skibiński, T. Inglot et al., “New tacrine analogs as acetylcholinesterase inhibitors - theoretical study with chemometric analysis,” *Molecules*, vol. 18, pp. 2878–2894, 2013.

[2] C. de los Ríos and J. Marco-Contelles, “Tacrines for Alzheimer’s disease therapy. III. The PyridoTacrines,” *European Journal of Medicinal Chemistry*, vol. 166, pp. 381–389, 2019.

[3] M. Mahdavi, M. Saeedi, L. Gholamnia et al., “Synthesis of novel tacrine analogs as acetylcholinesterase inhibitors,” *Journal of Heterocyclic Chemistry*, vol. 54, pp. 384–390, 2017.

[4] M. Bartolini and J. Marco-Contelles, “Tacrines as therapeutic agents for Alzheimer’s disease. IV. The tacripyrines and related annulated tacrines,” *Chemical Record*, vol. 19, no. 5, pp. 927–937, 2019.

[5] E. Fridjonsdottir, T. Vallianatou, I. Mantas et al., “Region-specific and age-dependent multitarget effects of acetylcholinesterase inhibitor tacrine on comprehensive neurotransmitter systems,” *ACS Chemical Biology*, vol. 17, no. 1, pp. 147–158, 2022.

[6] A. Akter, F. Islam, S. Bepary et al., “CNS depressant activities of Averrhoa carambola leaves extract in thiopental-sodium model of Swiss albino mice: implication for neuro-modulatory properties,” *Biologia*, vol. 77, no. 5, pp. 1337–1346, 2022.

[7] V. Tumiatti, A. Minarini, M. L. Bolognesi, A. Milelli, M. Rosini, and C. Melchiorre, “Tacrine derivatives and Alzheimers disease,” *Current Medicinal Chemistry*, vol. 17, no. 17, pp. 1825–1838, 2010.

[8] M. Przybyłowska, S. Kowalski, K. Dzierzbicka, and I. Inkiewicz-Stepniak, “Therapeutic potential of multifunctional tacrine analogues,” *Current Neuropharmacology*, vol. 17, pp. 472–490, 2019.

[9] C. Remya, K. V. Domeep, E. K. Reddy et al., “Neuroprotective derivatives of tacrine that target NMDA receptor and acetyl cholinesterase–design, synthesis and biological evaluation,” *Computational and Structural Biotechnology Journal*, vol. 19, pp. 4517–4537, 2021.

[10] M. Rahman, F. Islam, S. Afsana Mim et al., “Multifunctional therapeutic approach of nanomedicines against inflammation in cancer and aging,” *Journal of Nanomaterials*, vol. 2022, Article ID 4217529, p. 835, 2022.

[11] F. Islam, A. Akter, A. A. Mimi et al., “Neuropharmacological Effects of Chassalia curviflora (Rubiaceae) Leaves in Swiss Albino Mice Model,” *Archives of Razi Institute*, vol. 77, no. 2, pp. 881–890, 2022.

[12] F. H. Shaw and G. Bentley, “Some aspects of the pharmacology of morphine with special reference to its antagonism by 5-amino-acridine and other chemically related compounds,” *The Medical Journal of Australia*, vol. 2, pp. 868–874, 1949.
Oxidative Medicine and Cellular Longevity

[44] H. Chopra, S. Babi, I. Singh et al., "Nano-medicines in the Management of Alzheimer’s Disease: Current View and Future Prospects," Frontiers in Aging Neuroscience, vol. 2022, p. 726, 2022.

[45] M. G. Cavallo, P. Pozzilli, and R. Thorpe, "Cytokines and autoimmunity," Clinical and Experimental Immunology, vol. 96, pp. 1–7, 2008.

[46] P. Zhang, Z. Wang, C. Mou et al., "Design and synthesis of novel tacrine-dipicolylamine dimers that are multiple-target-directed ligands with potential to treat Alzheimer’s disease," Bioorganic Chemistry, vol. 116, 2021.

[47] A. Xu, F. He, X. Zhang et al., "Tacrine-hydroxamate derivatives as multi-target-directed ligands for the treatment of Alzheimer’s disease: design, synthesis, and biological evaluation," Bioorganic Chemistry, vol. 98, 2020.

[48] H. Yoo, G. Uras, P. Zhang et al., "Discovery of novel tacrine-pyrimidone hybrids as potent dual AChE/GSK-3 inhibitors for the treatment of Alzheimer’s disease," Journal of Medicinal Chemistry, vol. 64, pp. 7483–7506, 2021.

[49] J. Jeřábek, E. Ullassi, L. Guidotti et al., "Tacrine-resveratrol fused hybrids as multi-target-directed ligands against Alzheimer’s disease," European Journal of Medicinal Chemistry, vol. 127, pp. 250–262, 2017.

[50] E. D. AlFadly, P. A. Elzahhar, A. Tramarin et al., "Tackling neuroinflammation and cholinergic deficit in Alzheimer’s disease: multi-target inhibitors of cholinesterases, cyclooxygenase-2 and 15-lipoxygenase," European Journal of Medicinal Chemistry, vol. 167, pp. 161–186, 2019.

[51] H. L. Xu and S. Y. Xu, "Tacrine alleviates neuropathic pain in mice by mimicking the cell adhesion molecule 11," Signa Vitae, vol. 17, pp. 140–150, 2021.

[52] W. Ye, X. Gong, J. Xie et al., "AChE deficiency or inhibition decreases apoptosis and p53 expression and protects renal function after ischemia/reperfusion," Apoptosis, vol. 15, no. 4, pp. 474–487, 2010.

[53] R. V. Rao, E. Hermel, S. Castro-Obrero et al., "Coupling endoplasmic reticulum stress to the cell death program," The Journal of Biological Chemistry, vol. 276, pp. 33869–33874, 2001.

[54] E. Y. L. Liu, S. Mak, X. Kong et al., "Tacrine induces endoplasmic reticulum-stressed apoptosis via disrupting the proper assembly of oligomeric acetylcholinesterase in cultured neuronal cells," Molecular Pharmacology, vol. 100, pp. 456–469, 2021.

[55] Y. Liu, Y. Gong, W. Xie et al., "Microbubbles in combination with focused ultrasound for the delivery of quercetin-modified sulfur nanoparticles through the blood brain barrier into the brain parenchyma and relief of endoplasmic reticulum stress to treat Alzheimer’s disease," Nanoscale, vol. 12, pp. 6498–6511, 2020.

[56] E. G. Jordá, É. Verdaguer, A. Jiménez et al., "±-Huprine Y, (±)-huperzine a and tacrine do not show neuroprotective properties in an apoptotic model of neuronal cytoskeletal alteration," Journal of Alzheimer’s Disease, vol. 6, pp. 577–583, 2004.

[57] H. Zhang, S. Mak, W. Cui et al., "Tacrine(2)-ferulic acid, a novel multifunctional dimer, attenuates 6-hydroxydopamine-induced apoptosis in PC12 cells by activating Akt pathway," Neurochemistry International, vol. 59, pp. 981–988, 2011.

[58] R. Wang, J. Zhou, and X. C. Tang, "Tacrine attenuates hydrogen peroxide-induced apoptosis by regulating expression of apoptosis-related genes in rat PC12 cells," Molecular Brain Research, vol. 107, no. 1, pp. 1–8, 2002.

[59] A. Mansouri, D. Haozvi, V. Descatoire et al., "Tacrine inhibits topoisomerases and DNA synthesis to cause mitochondrial DNA depletion and apoptosis in mouse liver," Hepatology, vol. 38, no. 3, pp. 715–725, 2003.

[60] C. Gao, L. Zhong, L. Jiang, C. Geng, X. Yao, and J. Cao, "Phellinus linteus mushroom protects against tacrine-induced mitochondrial impairment and oxidative stress in HepG2 cells," Phytomedicine, vol. 20, pp. 705–709, 2013.

[61] X. Q. Xiao, R. Wang, and X. C. Tang, "Huperzine A and tacrine attenuate β-amyloid peptide-induced oxidative injury," Journal of Neuroscience Research, vol. 61, pp. 564–569, 2000.

[62] X. Q. Xiao, N. T. K. Lee, P. R. Carlier, Y. P. Pang, and Y. F. Han, "Bis(7)-tacrine, a promising anti-Alzheimer’s agent, reduces hydrogen peroxide-induced injury in rat pheochromocytoma cells: comparison with tacrine," Neuroscience Letters, vol. 290, no. 3, pp. 197–200, 2000.

[63] M. S. Lee, J. II Kim, T. Utsuki, N. G. Park, and H. R. Kim, "Cytotoxic effects of phlorofucofuroeckol A isolated from Ecklonia stolonifera against tacrine-treated HepG2 cells," Fitoterapia, vol. 83, no. 6, pp. 1060–1067, 2012.

[64] D. Alonso, I. Dorronsoro, L. Rubio et al., "Donepezil-tacrine hybrid related derivatives as new dual binding site inhibitors of AChE," Bioorganic Medicinal Chemistry, vol. 13, no. 24, pp. 6588–6597, 2005.

[65] Z. Q. Cheng, K. K. Zhu, J. Zhang et al., "Molecular-docking-guided design and synthesis of new IAA-tacrine hybrids as multifunctional AChE/BChE inhibitors," Bioorganic Chemistry, vol. 83, pp. 277–288, 2019.

[66] R. U. Pathak and G. P. Davey, "Complex I and energy thresholds in the brain," Biochimica et Biophysica Acta (BBA)-Bioenergetics, vol. 1777, pp. 777–782, 2008.

[67] M. Filosto, M. Scarpelli, M. S. Cotelli et al., "The role of mitochondrial impairment in neurodegenerative diseases," Journal of Neurology, vol. 258, no. 10, pp. 1763–1774, 2011.

[68] D. Kapogiannis and M. P. Mattson, "Perturbed energy metabolism and neuronal circuit dysfunction in cognitive impairment brain energy metabolism and cognitive impairment," Lancet Neurology, vol. 10, pp. 187–198, 2011.

[69] K. Leuner, K. Schulz, T. Schütt et al., "Peripheral mitochondrial dysfunction in Alzheimer’s disease: focus on lymphocytes," Molecular Neurobiology, vol. 46, no. 1, pp. 194–204, 2012.

[70] J. Korábečný, E. Nepovimová, T. Cikánková et al., "Newly developed drugs for Alzheimer’s disease in relation to energy metabolism, cholinergic and monoaminergic neurotransmission," Neuroscience, vol. 370, pp. 191–206, 2018.

[71] J. Hroudová, T. Nováková, J. Korábek, E. Uliassi, L. Guidotti et al., "Exploring the journey of newly developed drugs for Alzheimer’s disease in relation to energy metabolism, cholinergic and monoaminergic neurotransmission," Neuroscience, vol. 370, pp. 191–206, 2018.
[74] B. Berson, S. Renault, P. Letteron et al., "Uncoupling of rat and human mitochondria: a possible explanation for tacrine-induced liver dysfunction," *Gastroenterology*, vol. 110, pp. 1878–1890, 1996.

[75] S. Mitra, F. Islam, R. Das et al., "Pharmacological Potential of Avicennia alba Leaf Extract: An Experimental Analysis Focusing on Anti-oxidative, Anti-inflammatory, Analgesic, and Antidiarrheal Activity," *BioMed Research International*, vol. 2022, Article ID 7624189, p. 10, 2022.

[76] F. Costa Nunes, L. B. Silva, E. Winter et al., "Tacrine derivatives stimulate human glioma SF295 cell death and alter important proteins related to disease development: an old drug for new targets," *Biochimica et Biophysica Acta (BBA)-General Subjects*, vol. 1862, pp. 1527–1536, 2018.

[77] Q. Zhao, K. Katsumoto, K. Tsuneyama et al., "Diabetes-induced central cholinergic neuronal loss and cognitive deficit are attenuated by tacrine and a Chinese herbal prescription, Kangen-karyu: elucidation in type 2 diabetes db/db mice," *Journal of Pharmacological Sciences*, vol. 117, pp. 230–242, 2011.

[78] Y. M. Yi, L. Cai, Y. Shao, M. Xu, and J. L. Yi, "The protective role of tacrine and donepezil in the retina of acetylcholinesterase knockout mice," *International Journal of Ophthalmology*, vol. 8, no. 5, pp. 884–890, 2015.

[79] A. Alric, T. Mills, D. Carr et al., "Tacrine-induced liver damage: an analysis of 19 candidate genes," *Pharmacogenetcs and Genomics*, vol. 17, pp. 1091–1100, 2007.

[80] S. Mitra, M. S. Lami, T. M. Uddin et al., "Prospective multi-functional roles and pharmacological potential of dietary flavonoid narirutin," *Biomedicine & Pharmacotherapy*, vol. 150, Article ID 112932, 2022.

[81] E. Popugaeva, E. Pchitskaya, and I. Bezprozvanny, "Disregulation of neuronal calcium homeostasis in Alzheimer’s disease—a therapeutic opportunity," *Biochemical and Biophysical Research Communications*, vol. 483, pp. 998–1004, 2017.

[82] K. M. Kelly, R. A. Gross, and R. L. Macdonald, "Tetrahydroaminoacridine (THA) reduces voltage-dependent calcium currents in rat sensory neurons," *Neuroscience Letters*, vol. 132, no. 2, pp. 247–250, 1991.

[83] J. Marco-Contelles, R. Léon, C. De Los Ríos et al., "Tacrpyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer’s disease," *Journal of Medicinal Chemistry*, vol. 52, no. 9, pp. 2724–2732, 2009.

[84] N. N. Lermontova, A. E. Redkuzubov, E. F. Shevtsova, T. P. Serkova, E. G. Kireeva, and S. O. Bachurin, "Dimebon and tacrine inhibit neurotoxic action of beta-amyloid in culture and block L-type Ca(2+) channels," *Bulletin of Experimental Biology and Medicine*, vol. 132, no. 5, pp. 1079–1083, 2001.

[85] Z. Al Mahmud, T. B. Emran, N. Qais, S. C. Bachar, M. Sarker, and M. M. N. Uddin, "Evaluation of analgesic, anti-inflammatory, thrombolytic and hepatoprotective activities of roots of Premna esculenta (Roxb)," *Journal of Basic and Clinical Physiology and Pharmacology*, vol. 27, no. 1, pp. 63–70, 2016.

[86] V. Doležel, V. Lisá, and S. Tuček, "Effect of tacrine on intra-cellular calcium in cholinergic SN56 neuronal cells," *Brain Research*, vol. 769, no. 2, pp. 219–224, 1997.

[87] M. S. H. Kabir, M. M. Hossain, M. I. Kabir et al., "Hydrochemical screening, Antioxidant, Thrombolytic, alpha-amylase inhibition and cytotoxic activities of ethanol extract of Stednera colocasiafolia Koch leaves," *Journal of Young Pharmacists*, vol. 8, no. 4, pp. 391, 2016.

[88] R. León, C. de los Ríos, J. Marco-Contelles et al., "New tacrine-dihydropyridine hybrids that inhibit acetylcholinesterase, calcium entry, and exhibit neuroprotection properties," *Bioorganic Medicinal Chemistry*, vol. 16, pp. 7759–7769, 2008.

[89] T. Dutta, A. Paul, M. Majumder, R. A. Sultan, and T. B. Emran, "Pharmacological evidence for the use of Cissus assamica as a medicinal plant in the management of pain and pyrexia," *Toxicology and Biophysics Reports*, vol. 21, p. 100715, 2020.

[90] A. Hiremathad, R. S. Keri, A. R. Esteves, S. M. Cardoso, S. Chaves, and M. A. Santos, "Novel tacrine-hydroxyphenylbenzimidazole hybrids as potential multitarget drug candidates for Alzheimer’s disease," *European Journal of Medicinal Chemistry*, vol. 148, pp. 255–267, 2018.

[91] M. L. Crisman, "Tacrine: first drug approved for Alzheimer’s disease," *The Annals of Pharmacotherapy*, vol. 28, pp. 744–751, 1994.

[92] A. Minarini, A. Milelli, V. Tumiatti et al., "Cystamine-tacrine dimer: a new multi-target-directed ligand as potential therapeutic agent for Alzheimer’s disease treatment," *Neuropharmacology*, vol. 62, pp. 997–1003, 2012.

[93] S. S. Xie, J. S. Lan, X. B. Wang et al., "Multifunctional tacrine-trolox hybrids for the treatment of Alzheimer’s disease with cholinergic, antioxidant, neuroprotective and hepatoprotective properties," *European Journal of Medicinal Chemistry*, vol. 93, pp. 42–50, 2015.

[94] S. S. Xie, X. Wang, N. Jiang et al., "Multi-target tacrine-comuarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer’s disease," *European Journal of Medicinal Chemistry*, vol. 95, pp. 153–165, 2015.

[95] X. Zha, D. Lamba, L. Zhang et al., "Novel tacrine-benzofuran hybrids as potent multitarget-directed ligands for the treatment of Alzheimer’s disease: design, synthesis, biological evaluation, and X-ray crystallography," *Journal of Medicinal Chemistry*, vol. 59, no. 1, pp. 114–131, 2016.

[96] R. S. Keri, C. Quintanova, S. Chaves, D. F. Silva, S. M. Cardoso, and M. A. Santos, "New tacrine hybrids with natural-based cysteine derivatives as multitargeted drugs for potential treatment of Alzheimer’s disease," *Chemical Biology & Drug Design*, vol. 87, pp. 101–111, 2016.

[97] M. K. Hu, L. J. Wu, G. Hsiao, and M. H. Yen, "Homodimeric tacrine congeners as acetylcholinesterase inhibitors," *Journal of Medicinal Chemistry*, vol. 45, no. 11, pp. 2277–2282, 2002.

[98] J. J. Yan, J. Y. Cho, H. S. Kim et al., "Protection against β-amyloid peptide toxicity in vivo with long-term administration of ferulic acid," *British Journal of Pharmacology*, vol. 133, no. 1, pp. 89–96, 2001.

[99] R. Pi, X. Mao, X. Chao et al., "Tacrine-6-ferulic acid, a novel multifunctional dimer, inhibits amyloid-β-mediated Alzheimer’s disease-associated pathogenesis in vitro and in vivo," *PLoS One*, vol. 7, 2012.

[100] S. Mitra, A. M. Tareq, R. Das et al., "Polyphenols: a first evidence in the synergism and bioactivities," *Food Reviews International*, vol. 2022, pp. 1–23, 2022.

[101] L. Fang, B. Kraus, J. Lehmann, J. Heilmann, Y. Zhang, and M. Decker, "Design and synthesis of tacrine-ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates," *Chemistry Letters*, vol. 18, no. 9, pp. 2905–2909, 2008.

[102] M. I. Fernández-Bachiller, C. Pérez, N. E. Campillo et al., "Tacrine-melatonin hybrids as multifunctional agents for..."
Alzheimer’s disease, with cholinergic, antioxidant, and neuroprotective properties,” ChemMedChem, vol. 4, pp. 828–841, 2009.

[103] M. I. Rodríguez-Franco, M. I. Fernández-Bachiller, C. Pérez, B. Hernández-Ledesma, and B. Bartolomé, “Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties,” Journal of Medicinal Chemistry, vol. 49, pp. 459–462, 2006.

[104] L. Fang, D. Appenroth, M. Decker et al., “NO-donating tacrine hybrid compounds improve scopolamine-induced cognition impairment and show less hepatotoxicity,” Journal of Medicinal Chemistry, vol. 51, no. 24, pp. 7666–7669, 2008.

[105] P. W. Elsinghorst, J. S. Cieslik, K. Mohr, C. Tränkle, and M. Gütschow, “First gallamine-tacrine hybrid: design and characterization at cholinesterases and the M2 muscarinic receptor,” Journal of Medicinal Chemistry, vol. 50, no. 23, pp. 5685–5695, 2007.

[106] A. M. Tareq, S. Farhad, A. N. Uddin et al., “Chemical profiles, pharmacological properties, and in silico studies provide new insights on Cycas pectinata,” Heliyon, vol. 6, no. 6, p. e04061, 2020.

[107] P. Camps, X. Formosa, C. Galdeano et al., “Novel donepezil-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced β-amyloid aggregation,” Journal of Medicinal Chemistry, vol. 51, pp. 3588–3598, 2008.

[108] F. Islam, S. Mitra, M. H. Nafady et al., “Neuropharmacological and antidiabetic potential of Lannaea coromandelica (Hoult.) merr. leaves extract: an experimental analysis,” Evidence-Based Complementary and Alternative Medicine, vol. 2022, Article ID 6144733, 2022.

[109] S. Ahmed, A. Rakib, M. Islam et al., “In vivo and in vitro pharmacological activities of Taccia integrafolia rhizome and investigation of possible lead compounds against breast cancer through in silico approaches,” Clinical Phytoscience, vol. 5, no. 1, pp. 1–13, 2019.

[110] M. Mahdavi, R. Hariri, S. S. Mirfazli et al., “Synthesis and biological activity of some benzochromenoquinolines: tacrine analogs as potent anti-Alzheimer’s agents,” Chemistry & Biodiversity, vol. 16, no. 4, p. e1800488, 2019.

[111] M. M. Rahman, M. S. Rahaman, M. R. Islam et al., “Role of phenolic compounds in human disease: current knowledge and future prospects,” Molecules, vol. 27, no. 1, p. 233, 2021.

[112] H. Fu, W. Li, Y. Liu et al., “Mitochondrial proteomic analysis and characterization of the intracellular mechanisms of bis(7)-tacrine in protecting against glutamate-induced excitotoxicity in primary cultured neurons,” Journal of Proteome Research, vol. 6, no. 7, pp. 2435–2446, 2007.

[113] C. De los Ríos, J. L. Marco, M. D. C. Carreiras, P. M. Chinchón, A. G. García, and M. Villarroja, “Novel tacrine derivatives that block neuronal calcium channels,” Bioorganic Medicinal Chemistry, vol. 10, pp. 2077–2088, 2002.

[114] C. Zhang, Q. Y. Du, L. Di Chen et al., “Design, synthesis and evaluation of novel tacrine-multialkoxybenzene hybrids as multi-targeted compounds against Alzheimer’s disease,” European Journal of Medicinal Chemistry, vol. 116, pp. 200–209, 2016.

[115] J. Misik, J. Korabecny, E. Nepovimova, A. Kramarova, and J. Kassa, “Effects of novel tacrine-related cholinesterase inhibitors in the reversal of 3-quinuclidinyl benzilate-induced cognitive deficit in rats—is there a potential for Alzheimer's disease treatment,” Neuroscience Letters, vol. 612, pp. 261–268, 2016.

[116] E. I. Bahbah, S. Ghozy, M. S. Attia et al., “Molecular Mechanisms of Astaxanthin as a Potential Neurotherapeutic Agent,” Marine Drugs, vol. 19, no. 4, p. 201, 2021.

[117] G. A. K. Teponnou, J. Joubert, and S. F. Malan, “Tacrine, trolox and tryptoline as lead compounds for the design and synthesis of multi-target agents for Alzheimer’s disease therapy,” Open Medicinal Chemistry Journal, vol. 11, pp. 24–37, 2017.

[118] M. T. Kabir, M. S. Uddin, P. Jeandet et al., “Anti-Alzheimer’s Molecules Derived from Marine Life: Understanding Molecular Mechanisms and Therapeutic Potential,” Marine Drugs, vol. 19, no. 5, p. 251, 2021.

[119] Y. Chen, J. Zhu, J. Mo et al., “Synthesis and bioevaluation of new tacrine-cinnamic acid hybrids as cholinesterase inhibitors against Alzheimer’s disease,” Journal of Enzyme Inhibition and Medicinal Chemistry, vol. 33, pp. 290–302, 2018.

[120] H. Bouled, J. Ismaiil, H. Martin et al., “New (benz)imidazolopyridino tacrines as nonhepatotoxic, cholinesterase inhibitors for Alzheimer disease,” Medicinal Chemistry, vol. 9, no. 8, pp. 723–729, 2017.

[121] J. M. Roldán-Peña, V. Romero-Real, J. Hicke et al., “Tacrine-O-protected phenolines heterodrimers as multitarget-directed ligands against Alzheimer’s disease: selective subnanomolar BuChE inhibitors,” European Journal of Medicinal Chemistry, vol. 181, p. 111550, 2019.

[122] J. Zhu, H. Yang, Y. Chen et al., “Synthesis, pharmacology and molecular docking on multifunctional tacrine-feluric acid hybrids as cholinesterase inhibitors against Alzheimer’s disease,” Journal of Enzyme Inhibition and Medicinal Chemistry, vol. 33, pp. 496–506, 2018.

[123] N. Chufarova, K. Czarnecka, R. Skibiński, M. Cuchra, I. Majsterek, and P. Szymański, “New tacrine-acridine hybrids as promising multifunctional drugs for potential treatment of Alzheimer’s disease,” Archiv der Pharmazie, vol. 351, p. 1800050, 2018.

[124] K. Chand, E. Rajeshwari, S. M. Canedias, S. Cardoso, and M. A. Chaves, “Santos, tacrine-deferiprone hybrids as multi-target-directed metal chelators against Alzheimer’s disease: a two-in-one drug,” Metallomics, vol. 10, pp. 1460–1475, 2018.

[125] G. Li, G. Hong, X. Li et al., “Synthesis and activity towards Alzheimer’s disease in vitro: tacrine, phenolic acid and ligustrazine hybrids,” European Journal of Medicinal Chemistry, vol. 148, pp. 238–254, 2018.

[126] F. Mao, J. Li, H. Wei, L. Huang, and X. Li, “Tacrine-propargylamine derivatives with improved acetylcholinesterase inhibitory activity and lower hepatotoxicity as a potential lead compound for the treatment of Alzheimer’s disease,” Journal of Enzyme Inhibition and Medicinal Chemistry, vol. 30, no. 6, pp. 995–1001, 2015.

[127] S. Hamulakova, P. Poprac, K. Jomova et al., “Targeting copper(II)-induced oxidative stress and the acetylcholinesterase system in Alzheimer’s disease using multifunctional tacrine-coumarin hybrid molecules,” Journal of Inorganic Biochemistry, vol. 161, pp. 52–62, 2016.

[128] M. Fereidoonnozhad, A. Mostoufi, M. Eskandari, S. Zali, and F. Aliyan, “Multitarget drug design, molecular docking and PLIF studies of novel tacrine-coumarin hybrids for the treatment of Alzheimer’s disease,” Iranian Journal of Pharmaceutical Research: IJPR, vol. 17, no. 4, pp. 1217–1228, 2018.
R. Rajeshwari, K. Chand, E. Candeias, S. M. Cardoso, S. Chaves, and M. Amélia Santos, "New multitarget hybrids bearing tacrine and phenylbenzothiazole motifs as potential drug candidates for Alzheimer’s disease," *Molecules*, vol. 24, no. 3, p. 587, 2019.

G. F. Makhaeva, N. V. Kovaleva, N. P. Boltneva et al., "Conjugates of tacrine and 1,2,4-thiadiazole derivatives as new potential multifunctional agents for Alzheimer’s disease treatment: synthesis, quantum-chemical characterization, molecular docking, and biological evaluation," *Bioorganic Chemistry*, vol. 94, p. 103387, 2020.

Z. Xuan, X. Gu, S. Yan et al., "Dimeric Tacrine(10)-hupyrindone as a multitarget-directed ligand to treat Alzheimer’s disease," *ACS Chemical Neuroscience*, vol. 12, pp. 2462–2477, 2021.

M. V. Grishchenko, G. F. Makhaeva, Y. V. Burgart et al., "Conjugates of tacrine with salicylamide as promising multitarget agents for Alzheimer’s disease," *ChemMedChem*, vol. 2022, p. e202200080, 2022.

K. V. Sashidhara, R. K. Modukuri, P. Jadiya et al., "Discovery of 3-arylcoumarin-tetracyclic tacrine hybrids as multifunctional agents against Parkinson’s disease," *ACS Medicinal Chemistry Letters*, vol. 5, pp. 1099–1103, 2014.

M. S. Cousins, D. L. Carriero, and J. D. Salamone, "Tremulous jaw movements induced by the acetylcholinesterase inhibitor tacrine: effects of antiparkinsonian drugs," *European Journal of Pharmacology*, vol. 322, pp. 137–145, 1997.

N. Simola, S. Fenu, P. G. Baraldi, M. A. Tabrizi, and M. Morelli, "Blockade of adenosine a2A receptors antagonizes parkinsonian tremor in the rat tacrine model by an action on specific striatal regions," *Experimental Neurology*, vol. 189, pp. 182–188, 2004.

H. Miwa, J. Koh, Y. Kajimoto, and T. Kondo, "Effects of T-type calcium channel blockers on a parkinsonian tremor model in rats," *Pharmacology, Biochemistry, and Behavior*, vol. 97, pp. 656–659, 2011.

J. Trevitt, K. Kawa, A. Jalali, and C. Larsen, "Differential effects of adenosine antagonists in two models of parkinsonian tremor," *Pharmacology, Biochemistry, and Behavior*, vol. 94, no. 1, pp. 24–29, 2009.

M. Finn, A. J. Mayorga, A. Conlan, and J. D. Salamone, "Involvement of pallidal and nigral GABA mechanisms in the generation of tremulous jaw movements in rats," *Neuroscience*, vol. 80, pp. 535–544, 1997.

Y. M. Zhao, W. M. Li, N. T. K. Lee et al., "Bis(7)-tacrine prevents focal cerebral ischemic insults more potently than memantine in middle cerebral artery occlusion rats," *Acta Pharmacologica Sinica*, vol. 27, p. 375, 2006.

Y. F. Han, D. C. Wu, X. Q. Xiao et al., "Protection against ischemic injury in primary cultured astrocytes of mouse cerebral cortex by bis(7)-tacrine, a novel anti-Alzheimer’s agent," *Neuroscience Letters*, vol. 288, no. 2, pp. 95–98, 2000.

Y. Zhao, W. Li, P. C. Y. Chow et al., "Bis(7)-tacrine, a promising anti-Alzheimer’s dimer, affords dose- and time-dependent neuroprotection against transient focal cerebral ischemia," *Neuroscience Letters*, vol. 439, no. 2, pp. 160–164, 2008.

J. B. Li, Z. G. Lu, L. Xu, Q. Wang, Z. H. Zhang, and J. H. Fang, "Neuroprotective effects of bis(7)-tacrine in a rat model of pressure-induced retinal ischemia," *Cell Biochemistry and Biophysics*, vol. 68, no. 2, pp. 275–282, 2014.